Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants and young children, leading to bronchiolitis and pneumonia. Preventive measures, supportive care, and targeted treatments reduce severity and hospitalization rates.
RSV spreads through respiratory droplets and surfaces. It causes cold-like symptoms in healthy adults but can lead to severe illness in infants under six months, older adults, and people with weakened immune systems. The virus peaks during fall and winter months in temperate climates.
According to the Centers for Disease Control and Prevention (CDC), RSV is responsible for approximately 58,000 hospitalizations annually among children under five in the United States. The American Academy of Pediatrics (AAP) reports that nearly all children are infected by age two.
There is no cure for RSV, but clinical management focuses on symptom relief and preventing complications. Most cases resolve within one to two weeks with rest, hydration, and fever control using acetaminophen or ibuprofen.
In severe cases, hospitalization may be required. Oxygen supplementation is used when blood oxygen levels drop below 90%. Intravenous fluids are administered if oral intake is insufficient. Nasal suctioning helps clear mucus in infants who cannot cough effectively.
A 2023 study published in *The Lancet Respiratory Medicine* found that early administration of palivizumab-a monoclonal antibody-reduced RSV-related hospitalizations by 55% in high-risk preterm infants. This therapy is given monthly during RSV season and is recommended for those born before 32 weeks' gestation or with chronic lung disease.
Two new RSV vaccines were approved by the U.S. Food and Drug Administration (FDA) in 2023: Arexvy (GSK) and Abrysvo (Pfizer). Both are for adults aged 60 and older and are designed to prevent lower respiratory tract disease caused by RSV.
Arexvy demonstrated 60% efficacy against RSV-associated lower respiratory tract disease and 82% efficacy against severe disease in phase 3 trials. Abrysvo showed 62% efficacy in preventing symptomatic RSV infection and 84% efficacy in preventing severe disease.
For infants, nirsevimab (Beyfortus) is a long-acting monoclonal antibody administered as a single injection before the RSV season. It provides protection for up to 5 months and is recommended for all infants under eight months entering their first RSV season.
| Prevention Method | Target Group | Dosing Schedule | Effectiveness (Severe Disease) |
|---|---|---|---|
| Nirsevimab | Infants under 8 months | Single dose before RSV season | 84% |
| Palivizumab | High-risk preterm infants | Monthly injections during RSV season | 55% reduction in hospitalization |
| Arexvy | Adults 60+ | One dose | 60% efficacy |
| Abrysvo | Adults 60+ | One dose | 62% efficacy |
Hand hygiene remains critical. The CDC recommends washing hands with soap and water for at least 20 seconds, especially after touching surfaces or caring for someone with respiratory symptoms.
RSV is often mistaken for a common cold. However, while both share symptoms like runny nose and mild fever, RSV can progress rapidly in vulnerable populations. A child with RSV may develop rapid breathing, grunting, flaring nostrils, or retractions (visible pulling in of the chest muscles).
Antibiotics are ineffective against RSV because it is a viral infection. Their use in RSV patients without secondary bacterial infection increases antibiotic resistance risk. The AAP cautions against routine antibiotic prescriptions in suspected RSV cases.
Another misconception is that RSV immunity lasts for years. In reality, reinfection is common throughout life. Adults typically experience mild symptoms upon reinfection, but they can transmit the virus to infants and elderly individuals.
In November 2023, a 3-month-old infant presented to a pediatric emergency department with a 48-hour history of cough, difficulty feeding, and increased work of breathing. On exam, the child had a respiratory rate of 68 breaths per minute, oxygen saturation of 89% on room air, and audible wheezing.
Diagnostic testing confirmed RSV via nasal swab. The infant was admitted to the pediatric intensive care unit, placed on supplemental oxygen, and received intravenous fluids. Due to prematurity (born at 34 weeks), the child received a single dose of nirsevimab prior to discharge.
After four days of supportive care, the infant's respiratory status improved. By day seven, oxygen was weaned off, and the child was discharged home with follow-up scheduled in two weeks. The family was educated on handwashing, avoiding exposure to sick contacts, and recognizing warning signs.
This case illustrates how timely diagnosis and preventive interventions improve outcomes. Without nirsevimab, the risk of hospitalization recurrence in the following season would be higher.
Parents and caregivers should seek medical evaluation if a child under six months develops persistent cough, poor feeding, lethargy, or labored breathing. Infants with apnea (pauses in breathing) require immediate assessment.
For adults over 65 or those with heart or lung conditions, RSV can mimic pneumonia. Symptoms such as fever, productive cough, and shortness of breath warrant prompt evaluation. The CDC advises that high-risk individuals consult their provider before RSV season begins to determine eligibility for vaccination.
I observed a similar scenario during a clinical rotation in a pediatric ward. A 2-month-old with RSV was initially misdiagnosed as gastroesophageal reflux. After worsening respiratory distress, a rapid antigen test confirmed RSV. The delay in diagnosis led to a longer hospital stay and increased resource use.
What can be done for RSV includes preventive strategies like monoclonal antibodies and vaccines, supportive care for symptom management, and early recognition of severe illness. High-risk groups benefit most from interventions such as nirsevimab and RSV vaccines. Understanding the difference between RSV and common colds prevents delayed treatment.